Table 3.

Analysis of Outcome Measures Comparing Stented With Nonstented Subgroups

Group	Baseline	30 d	90 d	180 d	365 d
Villalta stented	17.0±5.17	10.7±5.49	9.3±6.49	8.7±6.13	8.4±5.51
Villalta nonstented	14.0±4.76	8.7±4.62	8.3±5.32	7.5±5.16	7.3±5.02
VCSS stented	12.6±5.39	8.4±4.64	7.6±4.98	7.3±4.59	6.8±3.50
VCSS nonstented	11.4±5.27	8.3±3.81	7.8±3.66	6.7±4.21	7.1±4.22
VEINES‐QOL stented	57.1±19.25	67.1±22.36	77.2±22.30	75.9±23.20	78.8±23.24
VEINES‐QOL nonstented	67.7±19.03	79.3±19.56	84.2±19.82	90.0±13.43	86.6±17.43
SF‐36 PCS stented	37.1±9.02	39.8±8.45	43.8±10.16	43.3±10.72	43.9±9.32
SF‐36 PCS nonstented	40.6±9.70	44.3±9.83	45.7±10.39	46.6±11.27	46.4±10.22

Data are given as mean±SD. At 365 days, P<0.001 for all measures, except SF‐36 PCS nonstented, for which P=0.0072. PCS indicates Physical Component Score; SF‐36, Short Form‐36; VCSS, Venous Clinical Severity Score; VEINES‐QOL, Venous Insufficiency Epidemiological and Economic Study–Quality of Life.